News | Magnetic Resonance Imaging (MRI) | May 29, 2025

Latest Swoop system software delivers a substantial increase in image quality for AI-powered portable MR brain imaging.


May 29, 2025 — Hyperfine, Inc., producer of the world’s first FDA-cleared AI-powered portable MRI system for the brain — the Swoop system — has announced FDA clearance of its next-generation software.

This tenth-generation release delivers a substantial increase in image quality for ultra-low-field MR imaging. Optive AI software enhances each stage of the imaging process   — from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity uniformity, and sharper anatomical detail. These advanced AI algorithms are applied across all sequences.

Earlier this year, Hyperfine released the software at select clinical sites where early users responded enthusiastically to the image quality improvements, with some reporting that image quality is approaching that of conventional 1.5 tesla MRI scanners. This feedback underscores the clarity and consistency of the new images that can enhance patient care.

“This software release marks the beginning of a transformative era for Hyperfine. The advanced AI algorithms integrated into our new software platform dramatically elevate image quality at ultra-low field strength, enabling more confident diagnoses at the point of care. We previewed Optive AI software at the recent American Society of Neuroradiology annual meeting and received outstanding feedback. It’s the strongest signal yet of where we’re headed—and how far AI-powered portable MRI imaging can go,” said Rafael O’Halloran, Hyperfine Vice President of Technology.

“Optive AI software is our tenth software release since initial FDA clearance and marks a critical inflection point in the evolution of Swoop® system technology—the first of two major technology milestones we have been looking forward to this year. The significant image quality enhancements enabled by Optive AI software will serve as a catalyst for our 2025 growth strategy, supporting expansion into new hospital sites of care and our entry into the neurology office market,” said Tom Teisseyre, Hyperfine Chief Operating Officer.

Hyperfine plans to initiate the rollout of Optive AI software to accounts in the third quarter of 2025.

For more information about the Swoop AI-powered portable MRI system, please visit hyperfine.io.


Related Content

News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 8, 2026 — Siemens Healthineers has received Food and Drug Administration clearance for the 70 cm bore Magnetom Flow ...

Time January 08, 2026
arrow
News | Stroke

Dec. 18, 2025 — Brainomix, a provider of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced ...

Time December 24, 2025
arrow
News | Information Technology

Dec. 16, 2025 — McCrae Tech has launched the world’s first health AI orchestrator called Orchestral. It is a health ...

Time December 23, 2025
arrow
News | RSNA 2025

Dec. 12, 2025 — At RSNA 2025, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
Subscribe Now